Showing 1 – 11 of 11
Relevance | Newest | Oldest |
  • Effects of Pitavastatin on Coronary Artery Disease and Inflammatory Biomarkers in HIV: Mechanistic Substudy of the REPRIEVE Randomized Clinical Trial

    Abstract Full Text
    open access has multimedia
    JAMA Cardiol. 2024; 9(4):323-334. 10.1001/jamacardio.2023.5661

    This substudy of a randomized clinical trial investigates the effects of pitavastatin on noncalcified coronary artery plaque using coronary computed tomography angiography and on inflammatory biomarkers as potential mechanisms for major adverse cardiovascular event prevention.

  • Effect of Torsemide vs Furosemide After Discharge on All-Cause Mortality in Patients Hospitalized With Heart Failure: The TRANSFORM-HF Randomized Clinical Trial

    Abstract Full Text
    free access
    JAMA. 2023; 329(3):214-223. 10.1001/jama.2022.23924

    This clinical trial compares the efficacy of torsemide vs furosemide in decreasing the risk of death from any cause among patients hospitalized for heart failure (regardless of ejection fraction).

  • Transforming Atrial Fibrillation Research to Integrate Social Determinants of Health: A National Heart, Lung, and Blood Institute Workshop Report

    Abstract Full Text
    is active quiz
    JAMA Cardiol. 2022; 8(2):182-191. 10.1001/jamacardio.2022.4091

    This study summarizes discussions from a National Heart, Lung, and Blood Institute workshop about knowledge gaps and research opportunities in social determinants of health research that address the distinctive aspects of atrial fibrillation.

  • Improving Enrollment of Underrepresented Racial and Ethnic Populations in Heart Failure Trials: A Call to Action From the Heart Failure Collaboratory

    Abstract Full Text
    is active quiz
    JAMA Cardiol. 2022; 7(5):540-548. 10.1001/jamacardio.2022.0161

    This Special Communication outlines strategies for heart failure clinical trials to promote enrollment of participants from underrepresented racial and ethnic minority groups.

  • Effect of Treatment With Sacubitril/Valsartan in Patients With Advanced Heart Failure and Reduced Ejection Fraction: A Randomized Clinical Trial

    Abstract Full Text
    free access has multimedia
    JAMA Cardiol. 2021; 7(1):17-25. 10.1001/jamacardio.2021.4567

    This randomized clinical trial evaluates the use of sacubitril/valsartan therapy compared with valsartan alone in US patients with advanced chronic heart failure.

  • Effect of Inorganic Nitrite vs Placebo on Exercise Capacity Among Patients With Heart Failure With Preserved Ejection Fraction: The INDIE-HFpEF Randomized Clinical Trial

    Abstract Full Text
    free access has multimedia
    JAMA. 2018; 320(17):1764-1773. 10.1001/jama.2018.14852

    This randomized clinical trial compares the effect of 4 weeks’ administration of inhaled, nebulized inorganic nitrite vs placebo on exercise capacity in patients with heart failure with preserved ejection fraction (HFpEF).

  • Variability in Ejection Fraction Measured By Echocardiography, Gated Single-Photon Emission Computed Tomography, and Cardiac Magnetic Resonance in Patients With Coronary Artery Disease and Left Ventricular Dysfunction

    Abstract Full Text
    open access online only
    ÁñÁ«ÊÓƵ Netw Open. 2018; 1(4):e181456. 10.1001/jamanetworkopen.2018.1456

    This multicenter diagnostic study determines the intermodality variability of left ventricular ejection fraction (LVEF) measured by echocardiography, gated single-photon emission computed tomography (SPECT), and cardiovascular magnetic resonance (CMR) in patients with coronary artery disease and left ventricular dysfunction.

  • Efficacy and Safety of Spironolactone in Acute Heart Failure: The ATHENA-HF Randomized Clinical Trial

    Abstract Full Text
    free access has multimedia
    JAMA Cardiol. 2017; 2(9):950-958. 10.1001/jamacardio.2017.2198

    This randomized clinical trial analyzes the effects of high-dose spironolactone vs usual care on N-terminal pro-B-type natriuretic peptide levels.

  • Effect of Natriuretic Peptide–Guided Therapy on Hospitalization or Cardiovascular Mortality in High-Risk Patients With Heart Failure and Reduced Ejection Fraction: A Randomized Clinical Trial

    Abstract Full Text
    free access
    JAMA. 2017; 318(8):713-720. 10.1001/jama.2017.10565

    This randomized clinical trial investigates whether reducing natriuretic peptide levels by titrating medication to reach the target of less than 1000 pg/mL in patients with heart failure and reduced ejection fraction improves clinical outcomes.

  • Effect of Oral Iron Repletion on Exercise Capacity in Patients With Heart Failure With Reduced Ejection Fraction and Iron Deficiency: The IRONOUT HF Randomized Clinical Trial

    Abstract Full Text
    free access
    JAMA. 2017; 317(19):1958-1966. 10.1001/jama.2017.5427

    This randomized clinical trial investigates the efficacy of oral iron supplementation for improvement of exercise capacity in adult patients with heart failure with reduced left ventricular ejection fraction.

  • One-Year Survival Following Early Revascularization for Cardiogenic Shock

    Abstract Full Text
    free access
    JAMA. 2001; 285(2):190-192. 10.1001/jama.285.2.190